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Abstract
Background
Several meta-analyses confirmed the five most prevalent human papillomavirus (HPV)
strains in women with and without cervical neoplastic diseases are HPV16, 18, 31, 52, and
58. HPV16/18 are the predominant oncogenic genotypes, causing approximately 70% of
global cervical cancer cases. The vast majority of the women studied in previous analyses
were from Europe, North America, Asia, and most recently Latin America and the Caribbe-
an. Despite the high burden of cervical cancer morbidity and mortality in Africa, a robust
meta-analysis of HPV genotype prevalence and distribution in African women is lacking.
Methods and Findings
We systematically searched 14 major databases from inception to August 2013 without lan-
guage restriction, following the Meta-Analysis of Observational Studies in Epidemiology
and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Seventy-one studies from 23 African countries were identified after screening 1162 citations
and data abstracted and study quality appraised from 195 articles. HPV type-specific preva-
lence and distribution was estimated from 17,273 cases of women with normal cervical cy-
tology; 1019 women with atypical squamous cells of undetermined significance (ASCUS);
1444 women with low-grade squamous intraepithelial lesion (LSIL); 1571 women with high-
grade squamous intraepithelial lesion (HSIL); and 4,067 cases of invasive cervical carcino-
ma (ICC). Overall prevalence of HPV16/18 were 4.4% and 2.8% of women with normal cy-
tology, 12.0% and 4.4% with ASCUS, 14.5% and 10.0% with LSIL, 31.2% and 13.9% with
HSIL, and 49.7% and 18.0% with ICC, respectively. Study limitations include the lack of ad-
equate data from Middle and Northern African regions, and variations in the HPV type-spe-
cific sensitivity of different genotyping protocols.
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Conclusions
To our knowledge, this study is the most comprehensive assessment of the overall preva-
lence and distribution of HPV genotypes in African women with and without different cervi-
cal neoplasias. We have established that HPV16/18 account for 67.7% of ICC cases
among African women. Based on our findings, we highly recommend the administration of
existing prophylactic vaccines to younger women not infected with HPV16/18 and an in-
crease in HPV screening efforts for high-risk genotypes to prevent cervical cancer.
Review registration:International Prospective Register of Systematic Reviews
CRD42013006558.
Introduction
Cervical cancer is the leading cause of mortality and years of life lost due to cancer in Africa [1]
and predominantly affects women ages 15–44 years [2]. For decades, 12 highly carcinogenic
human papillomavirus (HPV) genotypes have been recognized as the causative agent of cervi-
cal cancer [3,4]. Despite having the highest burden of risk factors associated with HPV infec-
tion, persistence, and progression to cervical cancer [5], comprehensive data on HPV genotype
prevalence and distribution in Africa are lacking. The use of Papanicolaou (Pap) smear screen-
ing [6] and HPV prophylactic vaccines [7–9] are effective in preventing cervical cancer in most
developed countries. However, their use in African countries remains very limited due to a va-
riety of socio-economic and logistical barriers [10–13].
To date, several global meta-analyses on the distribution of HPV genotypes have confirmed
the five most prevalent strains in women with normal cytology [14,15] and cervical neoplastic
diseases [16–24] to be HPV16, 18, 31, 52, and 58. HPV16 and 18 were identified as the pre-
dominant oncogenic genotypes, causing approximately 70% of global cervical cancer cases
[22], with the exception of women infected with HIV, in whom HPV58 is reported to be the
second most dominant strain behind HPV16 [20]. The vast majority of the women studied in
these investigations, however, were from Europe, North America [14,15,18–24], Asia [16], and
most recently Latin America and the Caribbean [17]. Data on African women in these studies
are highly variable and incomplete. Thus, the prevalence and distribution of HPV genotypes in
Africa among women with normal cervical cytology, neoplastic lesions, and invasive cervical
cancer (ICC) is required.
A comprehensive meta-analysis of HPV genotype prevalence and distribution among a
large sample size of African women is needed to inform local, national, regional, and global
policy to curb the spread of cervical cancer. In May 2013, the Global Alliance for Vaccine and
Immunization (GAVI) announced the availability of HPV vaccines (Gardasil and Cervarix) for
a reduced price of $4.50 per dose to low-income countries meeting the eligibility criteria
[13,25]. With clear indications that the GAVI Alliance is committed to subsidizing HPV vac-
cines for low-income countries [13,26–29], many African nations are beginning to design effec-
tive strategies that address the potential challenges of vaccine delivery and screening for HPV
and cervical cancer [13,28,29]. Epidemiological information on the prevalence and distribution
of genital HPV infection in Africa is critical for planning for vaccine implementation; evaluat-
ing the possible impact of existing prophylactic HPV vaccines; and determining the relevant
tools for HPV screening to prevent cervical cancer.
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To our knowledge, this systematic review and meta-analysis of HPV genotype prevalence
and distribution in Africa is the largest ever performed and includes 25,463 African women.
The goal of this study was to establish the overall and type-specific prevalence and distribution
of HPV genotypes among women with normal cervical cytology, neoplastic cervical lesions,
and cancer in all five World Health Organization (WHO) regions of Africa.
Methods
A systematic review protocol was performed adhering to the guidelines outlined in the Meta-
Analysis of Observational Studies in Epidemiology (MOOSE) for systematic reviews [30] and
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement
for reporting systematic reviews and meta-analyses [31,32] (See S1 Table). The investigators
wrote a protocol and registered it with the International Prospective Register of Systematic Re-
views (identification number CRD42013006558) in November 2013 [33].
Search Strategy
The search strategy was designed with a librarian (P.A.B.) to identify studies reporting HPV ge-
notypes associated with cervical cancer or neoplasia in women living in Africa by performing a
systematic search of literature databases from their earliest dates through August 27, 2013. The
search, without any language restrictions, was performed in PubMed/MEDLINE (NCBI),
Embase (Elsevier), Web of Science (Thomson), BIOSIS Preview (Thomson), Dissertations and
Theses Full Text (ProQuest), Cochrane Central Register of Controlled Trials (Wiley), African
Index Medicus (WHO), and POPLINE (K4Health). Exact strategies used to query each of
these databases are reported in S1 Appendix Detailed search strategy. We also attempted to
identify unpublished studies by examining ClinicalTrials.gov (NIH), International Clinical
Trial Registry Platform (WHO), European Union Clinical Trials Register (EMA), and System
for Information on Grey Literature in Europe (OpenGrey). The bibliographies of relevant re-
views and eligible studies were also examined for additional sources. Databases containing con-
ference proceedings or congress's annals, university theses, and experts were also consulted.
Studies, eligibility criteria, and quality assessment
We used a comprehensive strategy to identify studies that included women living in African
countries. Two reviewers (A.J.S. and J.G.O.) read the titles and abstracts to determine each
study’s eligibility for full text review if (i) the article and relevant data were accessible, (ii) at
least 10 women from an African country were included, (iii) cervical cytology/histology was
confirmed by exfoliated cervical cells or fixed/fresh biopsy, (iv) HPV genotype-specific preva-
lence of at least three HPV genotypes was calculated, and (v) HPV genotype prevalence was
calculated separately for each cervical lesion following the Bethesda classification [34,35].
There were no restrictions on the type of HPV assay method used. HPV genotypes were deter-
mined by molecular methods [signal amplified hybridization, polymerase chain reaction
(PCR), DNA sequencing, type-specific probes, reverse line-blot hybridization, in situ hybrid-
ization, southern blot hybridization, or microarray] or by immunological techniques (includ-
ing ELISA). Articles not meeting these five criteria were excluded. The reference lists of all the
articles included in the study were also perused for additional information including non-En-
glish articles/abstracts.
Based on the aforementioned pre-defined criteria, two separate reviewers (A.J.S. and R.K.
O.) independently reviewed full texts for data abstraction. When further clarification informa-
tion was required, authors were contacted via email. Discrepancies were resolved by discussion
or involvement of a third reviewer (J.G.O.). Two reviewers (A.J.S. and R.K.O.) independently
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assessed the methodological quality of studies and discrepancies were resolved by consensus
[17]. Methodological quality assessment of observational studies was assessed by a checklist of
essential items as outlined [24]. A list summarizing all 71 studies included for data abstraction
and quality assessment is provided in S2 Table.
Data items
If data or data subsets of the same population were published in multiple articles [36–38], only
the publication with the largest sample size was used and the other reports were used as supple-
mentary data. Two studies [39,40] had more detailed data in related doctoral theses, therefore
the additional data from the theses were used to supplement the journal articles. Jones et al.
[41] compared the results of HPV tests (clinician vs. self-administered), and data from the
method considered to be the most sensitive was extracted. Four studies included data from
women representing multiple countries [42–45]. Because the studies had clear lesion break-
downs, each of these articles was counted as an independent article in the analysis. Two studies
[46,47] reported data from multiple countries without separating individual women studied by
country. Though these papers had data broken down by lesion, at the regional level they were
grouped into a mixed region category. Okolo et al. [48] independently analyzed for ICC, how-
ever, the data on normal cytology was duplicated in Thomas et al. [49]. Thus, the latter publica-
tion was used as the source of data for abstraction.
Data extraction
The key information retrieved for analysis included: participant characteristics (population,
mean or median age, standard deviation of age), study characteristics (study design, period of
data collection, sample size), laboratory location where the samples were processed and geno-
typed, geographical settings (region according to WHO classification), country, distribution of
cases by histological type, tissue source, PCR primers (GP5+/6+, MY09/11, PGMY09/11,
SPF10 or individual laboratory designed primers), detailed HPV detection and genotyping
methodology, number of HPV positive women, and overall HPV prevalence where given. Data
was extracted for both high risk (HR) and low-risk (LR) HPV genotypes [50]. Studies reporting
multiple infections with any HPV genotype were also extracted. Specimens negative for beta-
globin were not included in the sample size. Cases were classified into five grades of cervical di-
agnosis by cytology and/or by histology as previously outlined [34,35]. This included women
with: 1) normal cervical cytology; 2) atypical squamous cells of undetermined significance
(ASCUS); 3) low-grade intraepithelial lesion (LSIL), including cervical intraepithelial neoplasia
grade 1 (CIN1); 4) high-grade squamous intraepithelial lesion (HSIL), including CIN2-3; and
5) ICC [including squamous cell carcinoma (SCC) and adeno/adenosquamous carcinoma].
Statistical analysis
Overall HPV prevalence was defined as the proportion of tested individuals that were positive
for any HPV infection expressed as a percentage [(the number of HPV positive women/the
total number tested)100]. Similarly, HPV type-specific prevalence by cytology or histology
was also calculated for those testing positive for the specific HPV type by cytological category
according to the 2001 Bethesda System [34,35]. HPV type-specific prevalence was defined as
the proportion of women testing positive for a specific HPV genotype among all HPV positive
women tested for that genotype. In HPV type–specific prevalence, only studies that tested for a
particular HPV type contributed to the analysis for that type, so sample sizes differed between
the type-specific analyses. Multiple HPV infections were separated into constituent types, thus
Prevalence of Human Papillomavirus Genotype amongWomen in Africa
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type-specific prevalence represents both single and multiple infections as previously defined
[17].
Statistical analysis was conducted as described by Ciapponi et al. [17], using StatsDirect
meta-analysis software (Cheshire, United Kingdom) and STATA 13.0 (College Station, TX).
Briefly, the sample size (N), number of cases for HPV type (rows), and each cytology/histology
classification (column) were calculated by summing the number of all study participants and
the number of events in each row/column combination. Raw prevalence was computed by di-
viding the number of events by sample size, N. Exact 95% confidence interval was computed
under binomial. Studies in which the HPV-type was not assessed or was not reported were ex-
cluded from the HPV type-specific analyses. Studies in which age was not reported were re-
corded and analyzed as missing age.
The computed proportions were arcsine square root transformed using the Freeman-Tukey
method to stabilize the variance [51]. The meta-analysis was then carried out on the trans-
formed proportions, with the inverse of the variance of the transformed proportion serving as
study-specific weight. The arcsine transformations were done to stabilize the variance of simple
proportions [17]. We further applied DerSimonian-Laird weights for the random effects model
[52] when heterogeneity between studies included in the analysis was found. The I-squared (I2)
statistic was used to quantify the heterogeneity between studies.
Additionally, a meta-regression using grouped logistic regression analysis adjusted for age-
group was performed to further identify the possible sources of heterogeneity. We then com-
puted lesion-specific age-adjusted prevalence for any HPV and HPV16 for each region. We
then used LSMEANS statement with the ILINK options in the SAS LOGISTIC procedure to
back transform log-odds into proportions and generate 95% confidence intervals.
Ethical statement. No institutional review board approval was required for this study.
Results
Selection of studies for review
A total of 1162 citations were retrieved and 195 full articles were reviewed. Data was abstracted
from 71 epidemiological studies with individual-level data meeting the inclusion criteria. The
study flow diagram is shown in Fig 1.
Study characteristics
Data were collected from studies conducted between 1968 [53] to 2010 [44]. With the excep-
tion of most studies from South Africa [41,44,54–68], a study fromMorocco [69], Ethiopia and
Sudan [42], all HPV genotyping of African participants were performed in laboratories in Eu-
rope (France, Spain, Great Britain, Italy, Sweden, the Netherlands, Belgium and Denmark),
Japan, or the United States of America (S4 Table). Fifty-six studies reported multiple infections
with any HPV type-specific. A total of 30,444 women from 23 African countries were recruited
to participate in the various studies included in the systematic review. Beta globin tests were
done on 27,915 sample specimens. Finally, HPV DNA testing was done on 25,463 sample spec-
imens from women who had a positive beta globin test result. Their distribution by cytological
type and geographical region is given in Table 1.
Out of 24,643 women tested for any HPV infection, 17,273 had normal cytology; 1,019 were
classified as ASCUS; 1,444 were diagnosed with LSIL; 1,571 were HSIL-positive; and 4,067 had
ICC. In addition, a total of 346 women were reported as HSIL or higher (either HSIL or ICC),
505 were classified as abnormal without separation into a specific lesion grade, and 257 were of
an unspecified low lesion type. The last three categories were expunged from further analysis.
Prevalence of Human Papillomavirus Genotype amongWomen in Africa
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Based on the WHO classification of geographic regions of Africa, Eastern Africa had the
highest number of women included in the study (10,246), followed by Western Africa (7,265),
Southern Africa (4,983), and Northern Africa (2,510) (Table 1). Middle Africa was the least
represented region, including only 30 women from two studies (Equatorial Guinea and Demo-
cratic Republic of Congo, formerly Zaire). South Africa (4,962) contributed the largest study
size followed by Tanzania (4,398), Senegal (2,360), Nigeria (2,289) and Kenya (2,034). Moroc-
co, Cote d’Ivoire, and Algeria each contributed over 1,000 women to the study. Each of the re-
maining 15 countries had fewer than 1,000 women included in the study. Two studies [46,47]
included 429 women from three different countries without identifying the subjects to their
specific country of origin.
Fig 1. Study flow diagram. Abbreviation: ASCUS: Atypical squamous cells of undetermined significance; LSIL: Low-grade squamous intraepithelial lesions;
HSIL: High-grade squamous intraepithelial lesions; ICC: Invasive cervical cancer (this includes SCC and ADC).
doi:10.1371/journal.pone.0122488.g001
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Meta-analysis results according to Bethesda Classification
The meta-analysis of HPV type-specific prevalence by lesion types according to the Bethesda
classification of women with normal cervical cytology and cervical neoplastic lesions (ASCUS,
LSIL, HSIL and ICC) are presented in Table 2. Further sub-group analysis of the 71 studies
was performed based on source of tissues, country and Gross National Income (GNI) classifi-
cation according to the World Bank Table 3and S3 Table. There were no statistically signifi-
cant differences in all the sub-group analysis for any HPV in women with normal cervix,
neoplasia or ICC. Age-adjusted prevalence for any HPV and HPV16 categorized by region and
lesion type is provided in Table 4.
Heterogeneity was found to be substantial, ICC: I2 = 88.8%, 43 studies; HSIL I2 = 81.5%, 33
studies; LSIL I2 = 93.3%, 23 studies; ASCUS I2 = 98.5%, 15 studies; and Normal I2 = 99.1%, 42
studies, all p-values<0.001. Random effects age-group adjusted meta-analysis using logistic re-
gression analysis were performed for every HPV genotype.
Prevalence of HPV genotypes in women with normal cervical cytology
Systematic review included 42 studies testing for cervical HPV infection in 17,273 women with
normal cytology. This is the highest number of African women with normal cervical cytology
ever included in a single HPV prevalence meta-analysis study. Most of the women tested for
HPV infections were from Eastern Africa (n = 6,640), followed by Western Africa (n = 5,600),
Southern Africa (n = 3,030) and Northern Africa (n = 1,865). A total of 138 individuals were
from studies that contained mixed countries (Table 1). HPV16, 52, 35, 18, 58, 51, 45, 31, 53
and 56 were the ten most common genotypes in women with normal cervical cytology in de-
scending order (Table 2).
There was wide variation in any HPV infection rates based on region, with Southern Africa
(57.3%) having the highest prevalence, followed by Eastern Africa (42.2%), Western Africa
(27.8%), and Northern Africa (12.8%) (Fig 2left panel). Type-specific HPV16 and 18 were
higher among women with normal cervical cytology from Southern Africa compared to other
regions at 9.9% and 5.8% respectively (Fig 2). No study representing women fromMiddle Af-
rica met the inclusion criteria.
Overall, 39 studies stratified eligible women screened for HPV infection according to age
groups. Analysis of these studies revealed that the age group 25–34 years had the highest overall
HPV prevalence at 50.5% (95% CI: 37.1–63.8; I2 = 97.2%), closely followed by the age group
15–24 years with 48.2% (95% CI: 14.7–81.6; I2 = 96.6%). Age groups 35–44 and 45–54 years
had HPV prevalence of 36.1% (95% CI: 26.9–45.2; I2 = 99.3%) and 31.6% (95% CI: 14.9–48.3;
I2 = 99.2%), respectively, all p-values<0.001 (Table 3). Further lesion-specific age-adjusted
prevalence for any HPV and HPV16 for each region is provided in Table 4.
Prevalence of HPV genotypes in Women with ASCUS and LSIL
To date, only one meta-analysis of HPV type-specific prevalence among women from Africa
with ASCUS and LSIL exists [21]. However, in that study there were less than 300 women in-
cluded in each lesion type. Our meta-analysis included fifteen studies testing for HPV infection
in 1,019 women diagnosed with ASCUS. Most of the women tested for HPV infections were
from Eastern Africa (n = 440), followed by women fromWestern Africa (n = 326), Southern
Africa (n = 207) and Northern Africa (n = 46). Of the women tested for an HPV infection in
Middle Africa, none were diagnosed with ASCUS (Table 1).
HPV16, 52, 18, 35, 45, 51, 66, 53, 39 and 58 were the ten most common genotypes in
women with ASCUS (Table 2). The prevalence of type-specific HPV and distribution in
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women diagnosed with ASCUS for each geographic region is presented in Fig 2, in the second
panel from the left.
For LSIL, data from a total of 1,444 women from 23 studies were abstracted. A majority of
the patients were from Eastern (n = 605), followed by Southern (n = 521), Western (n = 286,
Northern (n = 24) and Middle (n = 8) (Table 1) Africa regions. HPV16, 35, 52, 18, 53, 56, 58,
51, 45 and 66 were the top ten most common genotypes in women with LSIL (Table 2). HPV
type specific prevalence and distribution by region for LSIL is summarized in (Fig 2, in the
third panel from the left).
Prevalence of HPV genotypes in high-grade intraepithelial lesions
Guan et al. [21] attempted to analyze African HPV genotype prevalence in high-grade lesions,
where only 185 out of 245 patient samples tested positive for HPV. In our systematic review,
33 studies comprising a total of 1,571 HSIL cases were included in the analysis. A majority of
HSIL cases came from Southern (n = 768), followed by Eastern (n = 563), Western (n = 102),
and Middle (n = 19) regions of Africa. Only 8 and 17 cases were from the Northern region and
mixed region, respectively.
HPV16, 18, 35, 52, 58, 33, 31, 53, 45 and 66 were the ten most frequently detected genotypes
in HSIL cases (Table 2). HPV type-specific prevalence and distribution by region for HSIL is
Table 4. Lesion specific age-adjusted prevalence for any HPV and HPV16 for each region.
Age Any HPV HPV16 Region Any HPV HPV16
N
or
m
al <25 36.0(32.3–39.9) 6.8(5.1–9.1) Eastern 33.1(31.6–34.5) 4.5(4.0–5.3)
25-<35 47.7(45.4–50.0) 5.9(5.0–7.1) Southern 58.5(56.2–60.7) 11.2(9.6–13.1)
35-<45 26.8(26.2–27.6) 4.1(3.7–4.5) Western 28.7(27.1–30.8) 4.2(3.5–5.0)
45-<55 25.3(23.8–26.9) 3.7(3.2–4.5) Middle - -
= >55’ - - Northern 16.9(14.9–19.2) 3.0(2.2–4.2)
A
S
C
U
S <25 - - Eastern 60.2(55.4–64.8) 15.6(11.8–19.7)
25-<35 65.0(58.6–71.0) 6.6(4.0–10.7) Southern 62.7(55.7–69.2) 6.3(3.8–10.1)
35-<45 41.2(37.9) 13.5(11.3–16.1) Western 29.6(23.8–36.3) 1.7(0.9–3.3)
45-<55 - - Middle - -
= >55’ - - Northern - -
LS
IL <25 100(0–100) 10.0(2.5–32.4) Eastern - -
25-<35 76.0(72.6–79.0) 16.8(14.2–19.8) Southern - -
35-<45 70.8(67.4–73.9) 10.8(8.7–13.2) Western - -
45-<55 100(0–100) 100(0–100) Middle - -
= >55’ - - Northern - -
H
S
IL <25 100.0(0–100) 5.6(0.7–3.1) Eastern - 27.2(17.3–40.0)
25-<35 81.5(77.7–84.7) 28.6(24.7–32.8) Southern - 28.9(18.2–42.7)
35-<45 80.0(73.1–85.4) 31.8(29.1–34.7) Western - 26.2(14.5–42.7)
45-<55 85.6(57.2–96.4) 64.3(37.6–84.3 Middle - -
= >55’ - - Northern - -
IC
C <25 - - Eastern 91.4(89.9–92.9) -
25-<35 91.7(89.4–93.6) 47.5(43.7–51.3) Southern 82.1(77.3–86.0) -
35-<45 88.2(86.2–90.0) 47.2(44.3–50.2) Western 87.3(84.4–89.7) -
45-<55 91.1(89.7–92.4) 52.8(50.4–55.1) Middle -
= >55’ - 49.9(45.7–54.1) Northern 89.0(85.2–91.9) -
'-' Age-group adjusted prevalence cannot be estimated because of sparse data.
doi:10.1371/journal.pone.0122488.t004
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summarized in (Fig 2). Western Africa reported the highest prevalence of HPV16 and 18 at
33% and 22.2% respectively for HSIL. In Eastern and Southern regions, HPV16 prevalence was
tied at 28%, followed by HPV 52 (16.5%) and HPV 35 (15.1%), respectively.
Overall, 30 studies stratified eligible women screened for HPV infection by age. Analysis of
these studies revealed that the age group 45–54 years had the highest overall prevalence of any
HPV for HSIL at 87.1% (95% CI: (67.3–107.0; I2 = 0.0%) as shown in Table 3.
Prevalence of HPV genotypes in cervical cancer
A total of 4,067 cases from 43 studies were included in the ICC systematic review analysis
(Table 1). A majority of the ICC cases were from the Eastern region (n = 1,905), followed by
Fig 2. The ten most common HPV genotypes by regions and lesion types according to Bethesda classifications, respectively. Type specific
prevalence is weighted by study size. The superscript numbers in brackets represent the number of studies included for the specific HPV genotype. There
was not enough data from the middle African region.
doi:10.1371/journal.pone.0122488.g002
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Western (n = 951), Northern (n = 517), Southern (n = 457) regions, and only three patients
were from the Middle Africa region. Two hundred and thirty-five patients were from mixed
regions.
HPV16, 18, 45, 35, 33, 52, 31, 58, 51 and 68 were the top ten most frequently detected geno-
types among ICC cases (Table 2). While HPV16, 18, 35, and 52 were the four most common
types in normal cytology through HSIL lesions; in ICC tissues HPV45 replaced HPV52 as the
third most common genotype (Table 2). Together HPV16, 18, and 45 accounted for 77.7% of
all ICC cases in African women.
HPV type-specific prevalence and distribution by region is presented in Fig 2. The preva-
lence of HPV16, 18, and 45 in ICC cases were 49.7% (95% CI: 48.2–51.2; I2 = 88.6%), 18.0%
(95% CI: 16.8–19.2; I2 = 78.2%) and 10.0% (95% CI: 9.1–10.9; I2 = 85.7%), respectively. HPV16
and 18 varied by region; in descending order: Northern (61%, and 22.4%), Eastern (54.4% and
21.0%), Southern (46.8% and 18%), and Western (44.1% and 11.7%) regions of Africa.
Discussion
Comprehensive data on the geographic distribution of specific HPV genotypes in women with
all grades of cervical diagnosis are crucial for estimating the baseline burden of disease, the fu-
ture impact of HPV vaccines on cervical cancer prevention, and the identification of optimal
HPV screening tools. To the best of our knowledge, our report is the largest meta-analysis to
date of HPV genotype distribution and prevalence in women from Africa by region, lesion
type, age group, publication year, and PCR primers for genotyping. Seventy-one studies
matched the inclusion criteria and were abstracted for systematic review and meta-analysis.
Each of the five sub-regions of African countries (n = 23) was fairly represented with the excep-
tion of the Middle region, where only two studies were included.
Overall, the prevalence of any HPV infection in Africa was higher than other world regions;
our meta-analysis determined the prevalence rates in women with normal cervical cytology
(29.3%), ASCUS (46.5%), LSIL (74.2%), HSIL (84.8%) and ICC (89.5%) [21]. Our study re-
vealed that by pooling several studies examining HPV infection among women with normal
cervical cytology, Southern Africa has the highest of any HPV infections at 57.3%, followed by
Eastern Africa (42.2%), Western Africa (27.8%) and Northern Africa (12.8%). The prevalence
of any HPV infection increased among women by cervical disease grade in all regions, except
Southern Africa. However, the inclusion in this analysis of various genotyping techniques with
varying sensitivities might impact the accuracy of HPV specific genotype prevalence.
Nevertheless, the four most common genotypes, HPV16, 18, 52 and 35, were identical from
normal cervical cytology through HSIL. In ICC cases, however, HPV45 replaced HPV52 as the
third most common genotype. The high prevalence rate of HPV45 in Africa was previously re-
ported among ICC cases [18,19,22,110,111]. Further analysis of women diagnosed with ICC by
region confirmed that despite the differences in prevalence of HPV16, 18 and 45, these three ge-
notypes remained the most common in all regions for ICC. HPV33 was the fourth most com-
mon in all regions except inWestern Africa, where it is HPV35. These findings suggest a higher
prevalence of HPV45 in ICC and HPV52 in HSIL than previously found [23]. The prevalence of
HPV16 and 18 were much greater in ICC cases than in HSIL cases (49.7% vs. 31.2% and 18.0%
vs. 13.9%, respectively). The combined prevalence of HPV16 and 18 in cases of ICC is 67.7%, in
agreement with the ~70% global estimate found by other meta-analyses [19,21–23].
While there has been a substantial push toward mass vaccination with either Gardasil or
Cervarix [112], until now there was insufficient data to demonstrate the high prevalence of
HPV16/18 in cases of ICC in all sub-regions of the African continent. Data from the present
study indicate that vaccines currently available could prevent nearly 70% of cervical cancer
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cases in all sub-regions of Africa. Moreover, a polyvalent vaccine in Phase III clinical trials
known to protect against HPV16, 18, 31, 33, 35, 45, 51, 52, and 58 could prevent nearly all
cases of cervical cancer in African women. Unfortunately, because most African countries are
currently unprepared to implement HPV vaccination, even the availability of this nonavalent
vaccine would leave an entire generation unprotected in Africa [113]. These barriers include
the long duration of time it would take for the vaccine to be ready for mass distribution, the ne-
gotiation of its cost, and the placement of infrastructure to deliver the vaccine to adolescent
girls at risk of developing cervical cancer [13,114]. Thus, other cancer prevention tools such as
cervical screening through visual inspection with acetic acid and/or Lugol’s iodine, or detection
of high-risk HPV genotypes may help reduce the high burden of cervical cancer morbidity and
mortality in the region.
Using the stringent inclusion and exclusion criteria outlined in our meta-analysis, six stud-
ies from Northern Africa qualified for data abstraction for women with normal cervical cytolo-
gy (n = 1,865) and ICC (n = 517). Notably, 83.4% of ICC cases were associated with either
HPV16 (61%) or 18 (22.4%) in the sub-region, the highest number ever reported from any part
of the globe. However, the prevalence of any HPV infection among women with normal cytolo-
gy was low (12.8%) compared to other regions which ranged between 27.8–57.3%. The preva-
lence of HPV16 and 18 is 2.9% and 0.9%, respectively. Since most of the women screened for
cervical cancers are adults over 18 years of age, low prevalence of HPV16 and 18 in the popula-
tion suggests that there is a wider window available for delivering HPV vaccine, particularly if
it is combined with HPV DNA screening among older women. A recent review on the burden
of HPV infections and related diseases in the extended Middle East and Northern Africa re-
ported very low prevalence of HPV infection in women with normal cervical cytology, similar
to current findings [115]. However, our study revealed a higher prevalence of HPV16/18
among women diagnosed with ICC than previously reported [115]. The high prevalence of
HPV16/18 in ICC in Northern Africa requires urgent attention such as encouraging the use of
culturally acceptable tools to increase cervical cancer screenings and HPV DNA testing among
the population so as to have a complete picture of the prevalence of HPV genotypes by all
stages of cervical cancer grade. Due to limited data, our study was unable to yield conclusive
HPV prevalence in women from Northern Africa diagnosed with ASCUS, LSIL and HSIL cer-
vical lesions, due to limited data. Of great concern to policy makers in Northern Africa region
is that very few interventions to create awareness about cervical cancer, implementation of cer-
vical cancer screening programs, HPV DNA testing, or use of prophylactic vaccines to prevent
HPV infection have been reported.
A majority of the population in Northern Africa share similar cultural and religious tradi-
tions and known to have more conservative views towards sexual behavior than countries in
sub-Saharan Africa. If indeed future studies in Northern Africa clearly indicate that a majority
of women in the region with normal cervical cytology have lower risk of any HPV infection
even at advanced ages (18–26 years), then it will be important to increase the age of vaccination
for Northern African girls up from the current WHO recommended 9–13 years to a much
older age [116]. The legal adult age is between 16–18 years in most countries, which could
serve as a more appropriate vaccination age for the region.
The increasing availability of additional tools to prevent and fight cervical cancer provides
an opportunity for all nations to implement cervical cancer control programs that are both
cost-effective and easier to deliver or to improve existing programs by saving additional lives
and reducing cost [117]. The GAVI Alliance, in an effort to close the gap in access to life-saving
vaccines [28], recently announced a deal with pharmaceutical industries to offer the HPV vac-
cine at US $4.50 per dose [28,29] to developing countries meeting GAVI’s eligibility criteria
[13]. To date, 19 sub-Saharan African countries have been approved to pilot HPV vaccine
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demonstration projects, however, despite the high prevalence of HPV16/18 in ICC cases in
Northern Africa, not a single country from the region has been approved for HPV vaccine sup-
port [29].
The implementation of one lifetime screening at age 35 with either visual inspection with
acetic acid or HPV DNA testing would reduce the risk of developing cervical cancer by 25%
and cost less than $500 per person per year of life saved [11]. However, the lack of laboratory
infrastructure for HPV genotyping in nearly the entire African continent, with the exception of
South Africa, Morocco and Ethiopia as shown in our study, should be a major concern to all
who are working to fight cervical cancer in Africa. In our systematic review, the majority of the
HPV DNA genotyping (for the studies eligible for data abstraction) was performed outside of
Africa in the USA, Japan or Europe. HPV DNA testing is currently the most sensitive and re-
producible cervical screening test [118], therefore, there is an urgent need to build the infra-
structure in Africa to facilitate efficient cervical screening.
The major contribution of our study to the current body of literature is the assessment of
25,463 women from all African regions of whom 46.8% were HPV infected. A further stratifi-
cation of specific HPV genotype prevalence by disease severity will help identify appropriate
tools for HPV genotyping and assess the future impact of HPV vaccines. However, the applica-
bility of this data throughout Africa is limited, since 95% of the studies were obtained from
Eastern, Western and Southern African regions, partially attributable to the lack of well-de-
signed studies in the remainder of Africa, especially Middle and Northern Africa. Indeed, qual-
ity studies meeting stringent meta-analysis criteria for inclusion were missing from 30 African
countries, thus future cervical cancer prevention policies should consider building laboratory
infrastructure in these countries.
The current WHO recommendations on cervical cancer screening are based on age [119],
however, only a few studies stratified the population studied by age. A majority of studies re-
ported mean or median age, which is not helpful in defining the prevalence of HPV infection
by age-group to determine an appropriate age to target for HPV DNA testing or cervical
cancer screening. This consideration should be factored in the design of future studies in the
continent.
Some of the limitations to our study include: (i) the inclusion of cross-sectional studies and
their inherent risk of bias; (ii) inclusion of studies that over sampled HIV-seropositive patients
in the analysis; and (iii) there may be lack of representativeness of HPV type specific prevalence
due to variation in different genotyping methods used and tissue sources. Finally, while we
made every effort to identify and include in our meta-analysis all eligible studies, it is possible
that we missed some.
Although previous research has established the relationship between HIV and HPV infec-
tion, the inter-relationship is not fully understood [63,102,120]. Of the estimated 35.3 million
individuals worldwide living with HIV/AIDS in 2012, approximately 70% are living in Africa
[121]. Women make up 60% of the HIV-infected population in Africa [121], and nearly 40%
of HIV seropositive individuals without cervical abnormalities test positive for HPV infection
[110]. Studies are underway in our group to specifically estimate the prevalence of HPV geno-
types among women living with HIV in Africa.
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